Results 311 to 320 of about 352,925 (341)

Doxorubicin

Reactions Weekly, 2020
  +4 more sources

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Lancet Oncology, The, 2014
Ian Judson, Jaap Verweij, Hans Gelderblom   +2 more
exaly  

Carfilzomib/doxorubicin/doxorubicin liposomal

Reactions Weekly, 2015
openaire   +1 more source

Doxorubicin

Reactions Weekly, 2023
openaire   +2 more sources

Tumour-associated macrophages as treatment targets in oncology

Nature Reviews Clinical Oncology, 2017
Alberto Mantovani, Federica Marchesi, Alberto Malesci   +2 more
exaly  

Doxorubicin

Reactions Weekly, 2021
openaire   +1 more source

Engineered Design of Mesoporous Silica Nanoparticles to Deliver Doxorubicin and P-Glycoprotein siRNA to Overcome Drug Resistance in a Cancer Cell Line

ACS Nano, 2010
Huan Meng, Tian Xia, Zongxi Li
exaly  

Doxorubicin-Tethered Responsive Gold Nanoparticles Facilitate Intracellular Drug Delivery for Overcoming Multidrug Resistance in Cancer Cells

ACS Nano, 2011
Yu-Cai Wang, Meng-Hua Xiong, Jun Wang
exaly  

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

Lancet, The, 2016
William D Tap, Robin L Jones, Anthony D Elias   +2 more
exaly  

Doxorubicin liposomal, Doxorubicin pegylated liposomal

2010
Ines Mader, Patrizia Fürst-Weger, Robert Mader, Elisabeth Nogler-Semenitz, Sabine Wassertheurer   +4 more
openaire   +1 more source